Please assess the completion status of the following clinical trial:

Trial Title: Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Parental or sibling history of asthma.~2. Child must be less than 24 months of age.~3. Presence of viral upper or lower respiratory tract symptoms.~Exclusion Criteria:~1. History of recurrent wheezing requiring systemic corticosteroids.~2. Prior history of lung disease.~3. Birth \< 36 weeks gestation.~4. Immunodeficiency~5. Treatment with ribavirin, systemic or inhaled corticosteroids during the RSV infection.~6. Congenital heart disease.~7. No history of parental or sibling asthma.~8. Less than 48 hour or more than 5 day duration of viral URI symptoms since the peak symptoms from RSV would be expected to occur from 2-5 days into course of infection.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Months
- Healthy Volunteers: t

Study Arms:
- Toll-like Receptor 4 -2026/GG Genotype (Type: None): Toll-like Receptor 4 (TLR4) -2026/GG Genotype of interest hypothesized to be associated with less inflammation during Respiratory Syncytial virus (RSV) infection
- Toll-like Receptor 4 -2026/AG and AA Genotypes (Type: None): Toll-like Receptor 4 (TLR4) -2026/AG and AA control genotypes hypothesized to be associated with more inflammation during respiratory syncytial virus (RSV) infection

Based on this trial design, predict the completion outcome and termination type (if applicable).